Thermo Fisher Scientific Inc. (NYSE: TMO) announced today the expiration and final results of the company’s previously announced tender offer (the “Offer”) to purchase for cash any and all of its outstanding 2.50% Convertible Senior Notes due 2023 (the “Convertible Notes”). The Offer expired at 12:00 midnight, New York City time, at the end of Thursday, December 17, 2009.
As of the expiration of the Offer, $282,334,000 in aggregate principal amount of Convertible Notes, representing approximately 95.6% of the aggregate outstanding principal amount of Convertible Notes, were validly tendered and not validly withdrawn. The company has accepted for purchase all Convertible Notes that were validly tendered and not validly withdrawn.
As previously announced by the company, the final purchase price per $1,000 principal amount of Convertible Notes was $2,072.4743. The company expects to settle the Offer on December 18, 2009 and to pay an aggregate of approximately $586.6 million, including accrued and unpaid interest to, but excluding, the settlement date, to purchase all of the Convertible Notes that were validly tendered and not validly withdrawn.
Source Thermo Fisher Scientific
Thermo Fisher Scientific continues to support the development of COVID-19 vaccines, therapies